Lifeward shareholders back Oratech share issuance

Lifeward Ltd. reported the results of its extraordinary shareholder meeting held on March 12, 2026.

Rhea-AI Filing Summary

Lifeward Ltd. reported the results of its extraordinary shareholder meeting held on March 12, 2026. Shareholders representing 7,252,783 ordinary shares, about 39.7% of the 18,293,776 shares outstanding as of January 20, 2026, were present or voted, forming a quorum.

Investors approved issuing ordinary shares to Oramed Pharmaceuticals Inc. for the acquisition of 100% of Oratech Pharma, Inc., and related warrants and convertible note issuances tied to that deal. They also approved electing two external directors effective at the Oratech closing, their compensation framework, increasing shares under the 2025 Incentive Compensation Plan, and an equity grant to CEO Mark Grant.

Shareholders further approved reappointing Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as independent auditor for the year ending December 31, 2026, with the board authorized to set its remuneration.

Insights

Equity & Governance Analyst

Shareholders cleared key equity, governance and audit items tied to the Oratech deal.

The meeting confirms broad shareholder support for equity issuance needed to complete the Oratech Pharma acquisition and its associated financing structure. Approval covers shares to Oramed as consideration, as well as shares from pre-funded warrants, other warrants and secured convertible notes connected to the transaction.

Governance changes include electing two external directors, defining their compensation, expanding the 2025 Incentive Compensation Plan, and granting equity to CEO Mark Grant. Reappointing Kost Forer Gabbay & Kasierer as auditor through the year ending December 31, 2026, maintains continuity in financial oversight. The overall impact depends on the eventual closing and integration of the Oratech acquisition.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lifeward (LFWD) shareholders approve regarding the Oratech acquisition?

Shareholders approved issuing ordinary shares to Oramed Pharmaceuticals as consideration for acquiring 100% of Oratech Pharma, plus additional shares issuable through related warrants and secured convertible notes, all described in the proxy statement tied to the Oratech transaction.

How many Lifeward (LFWD) shares were represented at the March 12, 2026 meeting?

An aggregate of 7,252,783 ordinary shares were present or voted, representing about 39.7% of the 18,293,776 ordinary shares outstanding as of the January 20, 2026 record date, which was sufficient to constitute a quorum for the extraordinary meeting.

Which director-related proposals did Lifeward (LFWD) shareholders approve?

Shareholders approved electing two directors as external directors under Israel’s Companies Law, contingent on and effective at the Oratech acquisition closing. They also approved the compensation framework for external directors who may serve from time to time under that role.

Did Lifeward (LFWD) shareholders approve changes to the 2025 Incentive Compensation Plan?

Yes. Shareholders approved increasing the number of shares available for grant under Lifeward’s 2025 Incentive Compensation Plan, allowing the company to issue additional equity-based awards in the future under that plan’s terms.

Was Lifeward (LFWD) CEO Mark Grant’s equity grant approved?

Yes. Shareholders approved an equity grant to Mark Grant, Lifeward’s President and Chief Executive Officer. The proposal passed with 1,656,670 votes for, 674,846 against, and 57,784 abstentions, alongside broker non-votes reported separately.

Who will serve as Lifeward (LFWD)’s independent auditor after the meeting?

Shareholders reapproved Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as independent registered public accounting firm for the year ending December 31, 2026, and authorized the board, via its audit committee, to fix the firm’s remuneration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/13/2026 - 08:16 AM Learn about SEC filing dates

false0001607962L300-00000002 Cabot Rd., Hudson, MAFloor 6Yokneam Ilit+508.251.11544.959.0123Ordinary Shares, par value NIS 0.25NASDAQ00016079622026-03-122026-03-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 12, 2026

Lifeward Ltd.

(Exact name of registrant as specified in its charter)

Israel		001-36612		Not applicable
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2 Cabot Rd., Hudson, MA		01749
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: +508.251.1154

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Shares, no par value		LFWD		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07          Submission of Matters to a Vote of Security Holders.

An aggregate of 7,252,783 ordinary shares, no par value each (the “Ordinary Shares”), of Lifeward Ltd. (the “Company”), or approximately 39.7% of the 18,293,776 Ordinary Shares issued and outstanding as of January 20, 2026, the record date for the Extraordinary General Meeting of Shareholders of the Company held on March 12, 2026 (the “Meeting”), were present or voted at the Meeting, constituting a quorum. The following proposals were voted upon at the Meeting, with the results of such voting as set forth below.  Each of the proposals received the requisite level of approval by shareholders. The proposals are described in greater detail in the Proxy Statement for the Meeting (the “Proxy Statement”).

Results of the Meeting

Proposal No. 1: To approve the Company’s issuance of Ordinary Shares, as described in the Proxy Statement, (a) to Oramed Pharmaceuticals Inc. (“Oramed”), as consideration for the acquisition of 100% of the outstanding shares of Oratech Pharma, Inc. (the “Oratech Acquisition”), (b) to Oramed, upon the exercise of pre-funded warrants to purchase Ordinary Shares and warrants to purchase Ordinary Shares, which will be issued to Oramed in connection with the Oratech Acquisition, and (c) to Oramed and certain investors, upon the conversion of secured convertible notes and upon the exercise of warrants to purchase Ordinary Shares, which will be issued to Oramed and such investors pursuant to a securities purchase agreement that was entered into in connection with the Oratech Acquisition.

For	Against	Abstain	Broker Non-Votes
1,854,591	470,084	64,625	4,863,483

Proposal No. 2: To approve the election of the two directors named in the Proxy Statement, contingent upon and effective as of the closing of the Oratech Acquisition, each as an “external director” (an “External Director”) within the meaning of the Israel Companies Law, 5759-1999, to serve for a three-year term effective as of the closing of the Oratech Acquisition.

For	Against	Abstain	Broker Non-Votes
1,906,767	409,347	73,186	4,863,483

Proposal No. 3: To approve the compensation of the External Directors who may serve from time to time.

For	Against	Abstain	Broker Non-Votes
1,327,050	1,020,019	42,231	4,863,483

Proposal No. 4: To approve an increase in the number of shares available for grant under the Company’s 2025 Incentive Compensation Plan.

For	Against	Abstain	Broker Non-Votes
1,257,961	1,072,889	58,450	4,863,483

Proposal No. 5: To approve an equity grant to Mr. Mark Grant, the Company’s President and Chief Executive Officer.

For	Against	Abstain	Broker Non-Votes
1,656,670	674,846	57,784	4,863,483

Proposal No. 6: To approve the reappointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the Company’s independent registered public accounting firm for the year ending December 31, 2026, and until the Company’s 2027 annual meeting of shareholders, and to authorize the Board, upon recommendation of the audit committee, to fix the remuneration of said independent registered public accounting firm.

For	Against	Abstain	Broker Non-Votes
6,175,644	573,100	504,039	0

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Lifeward Ltd.
	By:	/s/ Mark Grant
	Name:   Title:	Mark Grant Chief Executive Officer

Dated: March 12, 2026

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 21.5 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 15.7 KB